Modalis Therapeutics' (TYO:4883) patent application for CRISPR-GNDM(r) based gene therapy MDL-101 as a treatment for LAMA2-CMD was granted in Japan, according to a Friday filing.
LAMA2-CMD is a severe congenital muscular dystrophy caused by the absence of the LAMA2 protein, for which there are currently no effective treatments due to the gene's large size.
Modalis' CRISPR-GNDM technology offers a novel solution by increasing the expression of the LAMA1 gene to compensate for LAMA2 deficiency without introducing double-strand DNA breaks.
The patent, alongside the US orphan drug designation, strengthens Modalis' intellectual property and paves the way for securing patents in other major countries.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。